Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis
Open Access
- 16 September 2026
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1) , 804
Abstract
Background: Bone morphogenetic protein 10 (BMP10) has atrial-specific and vascular properties and may reflect both atrial and vascular pathophysiology. We investigated whether BMP10 levels were associated with new-onset atrial fibrillation (AF), major adverse cardiovascular events (MACE), and all-cause mortality after open revascularisation for symptomatic peripheral arterial disease (PAD) or carotid stenosis (CS). Methods: Patients scheduled for endarterectomy for symptomatic PAD or CS were enrolled. BMP10 concentrations were measured using a multiplex immunoassay. Clinical outcomes were obtained from medical records during one-year follow-up. Associations between BMP10 and outcomes were assessed using Cox proportional hazards regression. Results: A total of 210 patients were included (63% men; 61% underwent surgery for PAD). Women were older than men and had higher BMP10 levels. Forty patients had known preoperative AF. During one-year follow-up, 26 patients experienced MACE and 13 died. Among 170 patients without AF at baseline, 10 developed new-onset AF. In unadjusted Cox regression, higher BMP10 levels were associated with MACE (HR 1.01, 95% CI 1.00-1.03; p = 0.047) and all-cause mortality (HR 1.03, 95% CI 1.01–1.04; p < 0.001), but not with new-onset AF (HR 1.00, 95% CI 0.97–1.03; p = 0.80). Effect estimates were similar after adjustment for age and sex. Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations for MACE and all-cause mortality, although confidence intervals were wide; no corresponding pattern was observed for new-onset AF. Conclusions: In this exploratory cohort, higher BMP10 levels were associated with MACE and all-cause mortality after endarterectomy for symptomatic PAD or CS. Women had higher BMP10 levels than men. These findings should be interpreted cautiously and considered hypothesis-generating; larger studies are required to validate the observed associations.Keywords
All Related Versions
Funding Information
- Örebro University
This publication has 25 references indexed in Scilit:
- Association of atrial fibrillation burden and clinical profile with blood biomarkers: Results from the ISOLATION Ablation CohortHeart Rhythm O2, 2025
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2024
- Circulating BMP10 Levels Associate With Late Postoperative Atrial Fibrillation and Left Atrial Endomysial FibrosisJACC: Clinical Electrophysiology, 2024
- Catheter ablation of symptomatic atrial fibrillation: Sex, ethnicity, and socioeconomic disparitiesHeart Rhythm O2, 2022
- Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillationEuropean Heart Journal, 2022
- 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgeryEuropean Heart Journal, 2022
- Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery DiseaseEuropean Journal of Vascular and Endovascular Surgery, 2022
- Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillationScientific Reports, 2022
- Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2Journal of Biological Chemistry, 2017
- The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial CellsJournal of Biological Chemistry, 2016